Table 3.
Regression weights and standard errors for mixed model analyses predicting EMG in Acquisition and Extinction phases.
| Predictor | Acquisition | Extinction |
|---|---|---|
| Intercept | 57.03 (0.88)** | 56.10 (0.80)** |
| CStypeCS− | −1.76 (1.25) | 1.12 (1.12) |
| CStypeITI | −1.51 (1.25) | −4.41 (1.12) |
| Trial | −0.16 (0.21) | −1.24 (0.12)** |
| Trial*CStypeCS− | −1.45 (0.30)* | −0.09 (0.17) |
| Trial*CStypeITI | −0.58 (0.30)** | −0.07 (0.17)** |
| Condition | 0.02 (1.26) | −0.47 (1.13) |
| Condition*CStypeCS− | 0.61 (1.78) | −1.32 (1.60) |
| Condition*CStypeITI | 0.27 (1.78) | −0.02 (1.59) |
| Condition*Trial | −0.37 (0.30) | 0.13 (0.17) |
| Condition*Trial*CStypeCS− | 0.64 (0.42) | 0.03 (0.24) |
| Condition*Trial*CStypeITI | 0.18 (0.42) | 0.13 (0.24) |
Note. Reference category for CStype is the CS+ trial type. All analyses on the effects of tVNS were conducted using one-sided hypothesis tests. *p < 0.05, **p < 0.001.